Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 364

1.

Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.

Ye W, Hannigan B, Zalles S, Mehrotra M, Barkoh BA, Williams MD, Cabanillas ME, Edeiken-Monroe B, Hu P, Duose D, Wistuba II, Medeiros LJ, Stewart J, Luthra R, Roy-Chowdhuri S.

Cancer Cytopathol. 2019 Jan 8. doi: 10.1002/cncy.22098. [Epub ahead of print]

PMID:
30620446
2.

Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection.

Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJ.

J Mol Diagn. 2019 Jan;21(1):89-98. doi: 10.1016/j.jmoldx.2018.08.002.

PMID:
30577887
3.

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.

Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ.

Cancer. 2018 Dec 3. doi: 10.1002/cncr.31831. [Epub ahead of print]

PMID:
30508305
4.

ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features.

Olar A, Tran D, Mehta VP, Reinhardt A, Manekia JH, Garnovskaya M, Ellezam B, Luthra R, Sulman EP, Mohila CA, Campbell GA, Powell SZ, Fuller GN, Aldape KD, Adesina AM.

Clin Neuropathol. 2018 Nov 30. doi: 10.5414/NP301105. [Epub ahead of print]

PMID:
30499772
5.

Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients.

Bolivar AM, Luthra R, Mehrotra M, Chen W, Barkoh BA, Hu P, Zhang W, Broaddus RR.

Mod Pathol. 2018 Oct 12. doi: 10.1038/s41379-018-0158-8. [Epub ahead of print]

PMID:
30315273
6.

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.

Montes-Moreno S, Routbort MJ, Lohman EJ, Barkoh BA, Kanagal-Shamanna R, Bueso-Ramos CE, Singh RR, Medeiros LJ, Luthra R, Patel KP.

PLoS One. 2018 Sep 17;13(9):e0204218. doi: 10.1371/journal.pone.0204218. eCollection 2018.

7.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.

Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5.

8.

Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia.

Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP.

Haematologica. 2018 Aug 31. pii: haematol.2018.191148. doi: 10.3324/haematol.2018.191148. [Epub ahead of print]

9.

Poorly differentiated osteoclast-like giant cell variant of cutaneous squamous cell carcinoma: Uncovering its mutational landscape through massive parallel sequencing.

Ahmadi Moghaddam P, Singh R, Mahmoodi M, Mehrotra M, Benaim G, Luthra R, Paniz-Mondolfi A.

Pathol Res Pract. 2018 Nov;214(11):1898-1903. doi: 10.1016/j.prp.2018.08.017. Epub 2018 Aug 19. No abstract available.

PMID:
30146254
10.

Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.

Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S.

Hum Pathol. 2018 Dec;82:215-231. doi: 10.1016/j.humpath.2018.07.030. Epub 2018 Aug 4.

PMID:
30086334
11.

Higher body mass index is associated with better survival in patients with myelodysplastic syndromes.

Jabbar KJ, Yin CC, Bueso-Ramos CE, Luthra R, Medeiros LJ, Zuo Z.

Leuk Res. 2018 Aug;71:63-66. doi: 10.1016/j.leukres.2018.07.008. Epub 2018 Jul 10. No abstract available.

PMID:
30015105
12.

Challenges in next generation sequencing analysis of somatic mutations in transplant patients.

Chen H, Luthra R, Patel KP, Routbort M, Rashid A, Roy-Chowdhuri S, Lazar A, Broaddus R, Manekia J, Singh RR, Yemelyanova A.

Cancer Genet. 2018 Oct;226-227:17-22. doi: 10.1016/j.cancergen.2018.04.119. Epub 2018 May 10.

PMID:
30005850
13.

Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.

Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, Davies MA.

J Neuropathol Exp Neurol. 2018 Jul 1;77(7):628-635. doi: 10.1093/jnen/nly046.

PMID:
29873738
14.

Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.

Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD.

Mol Cancer Ther. 2018 Jul;17(7):1575-1584. doi: 10.1158/1535-7163.MCT-17-0871. Epub 2018 Apr 25.

PMID:
29695638
15.

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.

DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP.

Cancer. 2018 Jul 1;124(13):2704-2713. doi: 10.1002/cncr.31331. Epub 2018 Apr 6. Review.

PMID:
29682723
16.

Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.

Kurt H, Bueso-Ramos CE, Khoury JD, Routbort MJ, Kanagal-Shamanna R, Patel UV, Jorgensen JL, Wang SA, Ravandi F, DiNardo C, Luthra R, Medeiros LJ, Patel KP.

Am J Surg Pathol. 2018 May;42(5):569-577. doi: 10.1097/PAS.0000000000000970.

PMID:
29635257
17.

MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer.

Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR, Routbort MJ, Hong D, Medeiros LJ, Lu X.

Oncotarget. 2018 Feb 7;9(16):12959-12970. doi: 10.18632/oncotarget.24430. eCollection 2018 Feb 27.

18.

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors.

Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R.

Oncotarget. 2017 Oct 24;9(12):10259-10271. doi: 10.18632/oncotarget.21982. eCollection 2018 Feb 13.

19.

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing.

Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CY.

Oncotarget. 2018 Jan 3;9(9):8441-8449. doi: 10.18632/oncotarget.23878. eCollection 2018 Feb 2.

20.

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.

Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H.

Int J Hematol. 2018 Jun;107(6):689-695. doi: 10.1007/s12185-018-2422-6. Epub 2018 Feb 20.

PMID:
29464484
21.

Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling.

Roy-Chowdhuri S, Mehrotra M, Bolivar AM, Kanagal-Shamanna R, Barkoh BA, Hannigan B, Zalles S, Ye W, Duose D, Broaddus R, Staerkel G, Wistuba I, Medeiros LJ, Luthra R.

Mod Pathol. 2018 Jul;31(7):1036-1045. doi: 10.1038/s41379-018-0006-x. Epub 2018 Feb 20.

PMID:
29463880
22.

Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing.

Sabir SH, Krishnamurthy S, Gupta S, Mills GB, Wei W, Cortes AC, Mills Shaw KR, Luthra R, Wallace MJ.

PLoS One. 2017 Dec 27;12(12):e0189651. doi: 10.1371/journal.pone.0189651. eCollection 2017.

23.

Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.

Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR.

Br J Haematol. 2018 Dec;183(5):831-835. doi: 10.1111/bjh.15059. Epub 2017 Dec 19. No abstract available.

PMID:
29265180
24.

Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer.

Fujii T, Matsuda N, Kono M, Harano K, Chen H, Luthra R, Roy-Chowdhuri S, Sahin AA, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT.

Eur J Cancer. 2018 Jan;89:64-71. doi: 10.1016/j.ejca.2017.11.015. Epub 2017 Dec 9.

PMID:
29232568
25.

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S.

Clin Cancer Res. 2018 Mar 1;24(5):1062-1072. doi: 10.1158/1078-0432.CCR-17-2484. Epub 2017 Nov 27.

PMID:
29180604
26.

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z.

Br J Haematol. 2018 Jan;180(1):33-40. doi: 10.1111/bjh.15018. Epub 2017 Nov 21.

27.

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N.

Am J Hematol. 2018 Feb;93(2):277-285. doi: 10.1002/ajh.24972. Epub 2017 Nov 27.

PMID:
29134664
28.

Myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N.

Leuk Lymphoma. 2018 Jul;59(7):1672-1676. doi: 10.1080/10428194.2017.1397663. Epub 2017 Nov 9.

PMID:
29119847
29.

Mutations in algal and cyanobacterial Photosystem I that independently affect the yield of initial charge separation in the two electron transfer cofactor branches.

Badshah SL, Sun J, Mula S, Gorka M, Baker P, Luthra R, Lin S, van der Est A, Golbeck JH, Redding KE.

Biochim Biophys Acta Bioenerg. 2018 Jan;1859(1):42-55. doi: 10.1016/j.bbabio.2017.10.003. Epub 2017 Oct 21.

30.

Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle/desmoplastic melanomas.

Jour G, Andeen NK, Al-Rohil R, Aung PP, Mehrotra M, Duose D, Hoch B, Argenyi Z, Luthra R, Wistuba II, Prieto VG.

J Pathol. 2018 Jan;244(1):97-106. doi: 10.1002/path.4996.

PMID:
28991373
31.

Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.

Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3591-3599. doi: 10.1210/jc.2017-01039.

32.

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.

Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE.

Blood. 2017 Nov 9;130(19):2084-2091. doi: 10.1182/blood-2017-07-792143. Epub 2017 Aug 23.

33.

Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory.

Mehrotra M, Duose DY, Singh RR, Barkoh BA, Manekia J, Harmon MA, Patel KP, Routbort MJ, Medeiros LJ, Wistuba II, Luthra R.

PLoS One. 2017 Aug 2;12(8):e0181968. doi: 10.1371/journal.pone.0181968. eCollection 2017.

34.

Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.

Patel U, Luthra R, Medeiros LJ, Patel KP.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S62-S74. doi: 10.1016/j.clml.2017.02.015. Review.

PMID:
28760304
35.

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.

Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W, Tang G, Loghavi S, Luthra R, Yang W, Kantarjian HM, Hu S.

Blood Cancer J. 2017 Jul 14;7(7):e583. doi: 10.1038/bcj.2017.62. No abstract available.

36.

Pediatric Ventriculoperitoneal Shunts and their Complications: An Analysis.

Agarwal N, Shukla RM, Agarwal D, Gupta K, Luthra R, Gupta J, Jain S.

J Indian Assoc Pediatr Surg. 2017 Jul-Sep;22(3):155-157. doi: 10.4103/0971-9261.207624.

37.

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia.

Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes J.

Appl Immunohistochem Mol Morphol. 2019 Jan;27(1):33-39. doi: 10.1097/PAI.0000000000000526.

PMID:
28682832
38.

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S.

Blood. 2017 Aug 31;130(9):1125-1131. doi: 10.1182/blood-2017-05-783225. Epub 2017 Jul 3.

39.

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation.

Kanagal-Shamanna R, Loghavi S, DiNardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD.

Haematologica. 2017 Oct;102(10):1661-1670. doi: 10.3324/haematol.2017.167726. Epub 2017 Jun 28.

40.

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.

Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E.

Cancer. 2017 Oct 1;123(19):3717-3724. doi: 10.1002/cncr.30810. Epub 2017 Jun 13.

41.

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.

Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS.

Clin Cancer Res. 2017 Sep 15;23(18):5648-5656. doi: 10.1158/1078-0432.CCR-17-0291. Epub 2017 May 23.

42.

Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid.

Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra R.

J Mol Diagn. 2017 Jul;19(4):514-524. doi: 10.1016/j.jmoldx.2017.03.003. Epub 2017 May 12.

PMID:
28506684
43.

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.

Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5.

44.

Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.

Kanagal-Shamanna R, Hidalgo Lopez JE, Milton DR, Kim HR, Zhao C, Zuo Z, Janania Martinez M, Stingo F, Lee J, Luthra R, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE.

Am J Hematol. 2017 Aug;92(8):E168-E171. doi: 10.1002/ajh.24776. Epub 2017 May 30. No abstract available.

45.

Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples.

Mehrotra M, Luthra R, Abraham R, Mishra BM, Virani S, Chen H, Routbort MJ, Patel KP, Medeiros LJ, Singh RR.

Cancer Genet. 2017 Apr;212-213:24-31. doi: 10.1016/j.cancergen.2017.03.002. Epub 2017 Mar 20.

PMID:
28449808
46.

Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.

Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, Routbort MJ.

J Neuropathol Exp Neurol. 2017 Mar 1;76(3):179-188. doi: 10.1093/jnen/nlw119.

PMID:
28395087
47.

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.

Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S.

PLoS One. 2017 Mar 7;12(3):e0173345. doi: 10.1371/journal.pone.0173345. eCollection 2017. Erratum in: PLoS One. 2017 May 17;12 (5):e0178275.

48.

Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

Salem A, Loghavi S, Tang G, Huh YO, Jabbour EJ, Kantarjian H, Wang W, Hu S, Luthra R, Medeiros LJ, Khoury JD.

Am J Hematol. 2017 Jun;92(6):520-528. doi: 10.1002/ajh.24710. Epub 2017 Apr 6.

49.

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.

Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM.

J Mol Diagn. 2017 Mar;19(2):313-327. doi: 10.1016/j.jmoldx.2016.10.007. Epub 2017 Feb 7.

50.

Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.

Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R.

Oncotarget. 2017 Feb 14;8(7):10845-10857. doi: 10.18632/oncotarget.14802.

Supplemental Content

Loading ...
Support Center